Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor
about
RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasisInhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.Granzyme M expressed by tumor cells promotes chemoresistance and EMT in vitro and metastasis in vivo associated with STAT3 activation.Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxelNetwork-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer.The biological significance and clinical applications of exosomes in ovarian cancer.Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.Hepatocyte growth factor-like protein is required for prostate tumor growth in the TRAMP mouse model.Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.STAT3/PIAS3 levels serve as "early signature" genes in the development of high-grade serous carcinoma from the fallopian tube.Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.
P2860
Q34334385-02F65E57-7A8B-4E77-84C3-F39E992866E5Q34483617-9ADF3F02-5D7C-42E0-9813-886A421F55B2Q35742411-77C1858A-0137-442E-AD40-CE4BD2ADB4EEQ35742549-52DE2AEA-2BD9-4202-B0DB-1BE30F60B2CEQ35769650-D6E93D32-5343-41B3-B622-19F008534C2DQ37029851-7AE403C5-154D-477F-BDF6-1D959BB2F41EQ41573533-077C8526-14E3-4604-9672-A93440BD8054Q41814227-67C5D0C5-E292-41C4-8C6C-141CA680839EQ41863613-9DBE0374-59FA-446F-A2E3-5B8D909A7EDEQ47688490-7D4C1D73-F6CC-4319-A29B-6F284FE773AFQ48227188-628C1941-4B6A-48B1-8B18-C258117FF14CQ50020012-439C48F6-F458-4F6E-AF13-E333F8E08DA6Q50085792-21306217-AFBB-49AB-8111-C0CF9B93DC22Q50696151-DE23C749-4DE9-4EB1-A100-80844121FABCQ52595311-F2EAB234-AC6E-4176-BF82-782C71B5C871
P2860
Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@ast
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@en
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@nl
type
label
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@ast
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@en
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@nl
prefLabel
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@ast
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@en
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@nl
P2093
P2860
P356
P1433
P1476
Targeting constitutively-activ ...... using a novel STAT3 inhibitor
@en
P2093
Adrian Suarez
Brent J Tierney
Georgia A McCann
Hemant K Bid
Jianying Zhang
Karuppaiyah Selvendiran
Kellie S Rath
Kálmán Hideg
Periannan Kuppusamy
Peter Houghton
P2860
P304
P356
10.18632/ONCOSCIENCE.26
P577
2014-03-31T00:00:00Z